SUPPRESSION OF MYELOID DERIVED SUPPRESSOR CELLS AND IMMUNE CHECKPOINT BLOCKADE
Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
25.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!